326 related articles for article (PubMed ID: 34315420)
1. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
2. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
3. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
4. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
6. Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women.
Sugita B; Gill M; Mahajan A; Duttargi A; Kirolikar S; Almeida R; Regis K; Oluwasanmi OL; Marchi F; Marian C; Makambi K; Kallakury B; Sheahan L; Cavalli IJ; Ribeiro EM; Madhavan S; Boca S; Gusev Y; Cavalli LR
Oncotarget; 2016 Nov; 7(48):79274-79291. PubMed ID: 27813494
[TBL] [Abstract][Full Text] [Related]
7. circUSP42 Is Downregulated in Triple-Negative Breast Cancer and Associated With Poor Prognosis.
Yu J; Shen W; Xu J; Gong B; Gao B; Zhu J
Technol Cancer Res Treat; 2020; 19():1533033820950827. PubMed ID: 32938310
[TBL] [Abstract][Full Text] [Related]
8. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
9. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
10. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
[No Abstract] [Full Text] [Related]
11. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
[TBL] [Abstract][Full Text] [Related]
12. miR-518a-3p Suppresses Triple-Negative Breast Cancer Invasion and Migration Through Regulation of TMEM2.
Gan L; Yang H; Xiong Z; Yang Z; Wang T; Lyu G
Technol Cancer Res Treat; 2020; 19():1533033820977523. PubMed ID: 33251982
[TBL] [Abstract][Full Text] [Related]
13. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
[TBL] [Abstract][Full Text] [Related]
14. Deregulated miRNA Expression in Triple-Negative Breast Cancer of Ancestral Genomic-Characterized Latina Patients.
Almohaywi M; Sugita BM; Centa A; Fonseca AS; Antunes VC; Fadda P; Mannion CM; Abijo T; Goldberg SL; Campbell MC; Copeland RL; Kanaan Y; Cavalli LR
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685851
[TBL] [Abstract][Full Text] [Related]
15. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of microRNAs in triple-negative breast cancer.
Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
[TBL] [Abstract][Full Text] [Related]
17. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Circulating miRNAs in Lymph Node Metastasis for Colon Cancer.
Lee IH; Kim G; Kwak SG; Baek DW; Kang BW; Kim HJ; Park SY; Park JS; Choi GS; Hur K; Kim JG
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513887
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
[TBL] [Abstract][Full Text] [Related]
20. MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.
Ozcan O; Kara M; Yumrutas O; Bozgeyik E; Bozgeyik I; Celik OI
Tumour Biol; 2016 May; 37(5):6637-45. PubMed ID: 26643896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
